ABT-737, a small molecule cell-permeable Bcl-2 antagonist that acts by mimicking BH3
INTRODUCTION
Aberrant expression of the antiapoptotic Bcl-2 family of proteins in human cancer is correlated with poor outcomes after standard chemotherapy. One approach to overcoming this blockade is the development of compounds such as ABT-737, a cell permeable small molecule Bcl-2 family antagonist that is capable of binding to Bcl-2, Bcl-x L , and Bcl-w, but does not block the activity of Mcl-1, Bfl-1/A1 and Bcl-B (1). This agent functions by displacing BH3 proteins, such as Bim, from these proteins activating Bax and Bak to induce apoptotic cell death (2) and has the ability to kill leukemia and lymphoma (1), multiple myeloma (3), glioblastoma (4) and small cell lung cancer cell lines (5) . Based on these results an orally active form of this compound, ABT-263, has entered clinical trials (6, 7) .
Emerging results demonstrate that ABT-737, especially when used to treat solid tumors including lung, prostate and renal cancers (1, 8) , can be ineffective at inducing apoptosis.
Resistance to ABT-737 is in part mediated by the elevated expression of Mcl-1 or Bfl-1/A1 which are not capable of binding this compound (9, 10) . Carcinomas exhibit elevated levels of endogenous Mcl-1 and are resistant to killing by this agent (8, 11) .
Alternatively, we have suggested (8) 
Real-Time PCR, Microarray, and Luciferase Assays.
Real-time PCR, primers and microarray gene expression profiling are performed as described in detail in the Supplemental Experimental Procedures. Dual luciferase assay was performed (8) and is described in detail in the Supplemental materials.
RESULTS

ABT-737 induces the transcriptional activation of IL-6 and IL-8.
We have identified a group of cancer cell lines (8) that are resistant to the proapoptotic activity of ABT-737.
To examine changes in gene transcription after ABT-737 treatment of PV-10 cells, which are a kidney cancer cell line resistant to apoptosis induced by this agent, we carried out microarray analysis using an Affymetrix human gene chip (U133 Plus 2.0 Array) with mRNA from cells either treated with vehicle or ABT-737 for 24 h. Our analysis of these results revealed that more than 430 genes were significantly changed (> 2-fold, P<0.05) either up or down after exposure to ABT-737 ( Figure 1A) . Genes that are regulated more than 4-fold by ABT-737 are shown in (Supplementary Table S1 ). IL-6, IL-8, and IL-11 and chemokines CXCL2 and CXCL5 and other secreted cytokines/chemokines are induced more than 2-fold ( Figure 1B) . Quantitative real-time PCR (qT-PCR) analysis of IL-6 and IL-8 demonstrated that ABT-737, but not its inactive enantiomer, was able to induce changes in mRNA levels confirming the microarray analysis ( Figure 1C ).
Significant increases in other mRNA transcripts including IL-11, CXCL2, CXCL5, IRF1, and GADD45A were also confirmed by qT-PCR analysis (Supplementary Figure S1) . Figure S1) . To determine whether the change in IL-6 and IL-8 mRNA levels is mirrored with a change in the protein produced, we performed an ELISA assays.
Secretion of IL-6 and IL-8 protein was both increased in PV-10 cells in response to ABT-737 treatment ( Figure 1D ). To examine whether these gene changes were seen in other cell lines after ABT-737 treatment, we studied the effect of ABT-737 on six additional protein levels (Figure 7A ), but no change in p16 mRNA levels (Supplementary Figure   S1A) . As predicted from the changes in p53, the upregulation of p21 protein levels occurred at the transcriptional level and the enantiomer had no activity in regulating p21
( Figure 7B ). To examine whether ABT-737-induced-increases in p21 levels could account for the growth arrest seen after treatment, we measured the effect of ABT-737 on the activity of the Cdk2 protein, a kinase that plays an important role both in controlling the G1/S transition, and has a clear impact on the induction of oncogene-induced senescence (31). The Cdk2 kinase was immunoprecipitated from treated cells and incubated with histone H1 as a substrate. We find that ABT-737 treatment inhibits Cdk2 activity in a dose-dependent fashion in both PV-10 and 22Rv1 cells (Supplementary
Figure S7).
To examine whether the p53 pathway is essential for the induction of senescence, we generated a pool of 22Rv1 cells expressing dominant-negative p53 (DN p53) (17) .
Western blot analysis confirmed that after ABT-737 treatment over expression of DN p53 caused a substantial reduction in p21 ( Figure 7C ) and inhibited the ability of ABT-737 to induce SA-β-Gal ( Figure 7D) . for example in the repression of CD28 expression in aging lymphocytes (33) . More recently, activation of both CAD and caspase-3 have been shown to be necessary for myoblast differentiation and to induce p21 mRNA transcription (34) . Caspase activation was sufficient to induce biologic changes but insufficient to induce apoptosis. Activation of ROS production has been associated both with the regulation of caspase-3 activity and the induction of senescence (35, 36) . As suggested by the ability of NAC to partially block both caspase-3 activation and senescence the addition of ABT-737 to these tumor cells ROS plays a role in low level caspase-3 activation. Similarly, it has been reported that peroxynitrite leads to senescence of red blood cells through caspase-3 activation (37).
Very low doses of γ-radiation induce only transient DNA damage that is quickly repaired.
Higher doses of radiation are needed for prolonged DNA-damage that then leads to the induction of senescence-associated markers (26) , and still higher doses are needed to induce cell death. Finally the amount and extent of DNA damage has been linked to the ability of cells to increase the secretion of the immune mediator cytokines/chemokines associated with senescence (38) , similar to what is seen here.
Increases in p21 are an essential control point in senescence (30) not only because modulation of this protein blocks cyclin-dependent protein kinases, but also because p21
regulates the transcriptional activation of multiple genes necessary for the induction of the senescent phenotype (39) . In multiple tumor types activation of the p53 (40) has been shown to be essential for the induction of senescence. Using over expression of dominant-negative p53, we demonstrate that the p53 pathway is also necessary for ABT-737 senescence in the 22Rv1 prostate tumor cells. Other DNA damaging agents require 
